AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Exelixis: From Cancer Therapeutics to Multi-Franchise Oncology Company with Zanzalintinib.
ByAinvest
Tuesday, Aug 5, 2025 9:51 am ET1min read
Exelixis operates in the global oncology therapeutics market, one of the fastest-growing sectors in biopharma. The company's cabozantinib franchise, marketed as CABOMETYX and COMETRIQ, generated $1.81 billion in 2024. Exelixis is transitioning into a multi-franchise oncology company with its lead pipeline candidate, zanzalintinib, a third-generation TKI with enhanced selectivity for VEGF receptors, MET, and TAM kinases. Positive top-line results from STELLAR-303 in metastatic CRC were announced, positioning the company to seek regulatory approval in this indication. Exelixis projects zanzalintinib could achieve U.S. revenues of $5 billion by 2033, surpassing the cabozantinib franchise.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet